Table 3. Response Rates to FCR3 by Pretreatment Characteristics.
| Patient characteristic | N | ORR, N (%) | CR, N (%) | P-value1 |
|---|---|---|---|---|
|
| ||||
| All | 64 | 62 (97) | 48 (75) | --- |
|
| ||||
| Age (y) | 0.51 | |||
| <55 | 19 | 19 (100) | 16 (84) | |
| 55-69 | 36 | 35 (97) | 26 (72) | |
| ≥70 | 9 | 8 (89) | 6 (67) | |
|
| ||||
| WBC (K/μL) | 0.77 | |||
| <100 | 34 | 33 (97) | 25 (74) | |
| ≥100 | 30 | 29 (97) | 23 (77) | |
|
| ||||
| β2-microglobulin (mg/L) | <0.01 | |||
| ≤3.8 | 34 | 34 (100) | 30 (88) | |
| >3.8 | 30 | 28 (93) | 18 (60) | |
|
| ||||
| Rai stage | 0.11 | |||
| 0-II | 46 | 45 (98) | 37 (80) | |
| III-IV | 18 | 17 (94) | 11 (61) | |
|
| ||||
| CD38 expression | 0.33 | |||
| <30% | 42 | 40 (95) | 33 (79) | |
| ≥30% | 18 | 18 (100) | 12 (67) | |
|
| ||||
| IGHV mutational status | 0.90 | |||
| Mutated (≥2%) | 16 | 16 (100) | 12 (75) | |
| Unmutated (<2%) | 45 | 43 (96) | 33 (73) | |
|
| ||||
| Zap-70 flow | 0.28 | |||
| Negative (<20%) | 18 | 18 (100) | 14 (78) | |
| Positive (≥20%) | 21 | 20 (95) | 23 (62) | |
|
| ||||
| FISH, bone marrow | ||||
| Negative | 13 | 13 (100) | 10 (77) | |
| del13q | 10 | 10 (100) | 9 (90) | 0.29 |
| Trisomy 122 | 10 | 10 (100) | 8 (80) | |
| del11q3 | 13 | 13 (100) | 11 (85) | |
| del17p | 1 | 0 (0) | 0 (0) | |
1
P-values are comparing CR rates vs. any response less than CR.
2
Includes 2 patients with concomitant del13q.
3
Includes 10 patients with concomitant del13q and excludes the one patient with concomitant del17p.
ORR, overall response rate; CR, complete remission; WBC, white blood cells; IGHV, immunoglobulin variable heavy chain; FISH, fluorescent in situ hybridization